News

Sugarmade (SGMD) Issues Shareholder Letter and Corporate Update (SGMD)

Holly Neff Cannabis Corner, News May 02nd, 2022

NEW YORK, May 2, 2022 (GLOBE NEWSWIRE) — via InvestorWire Sugarmade, Inc. (OTC Pink: SGMD) (“Sugarmade”, “SGMD” or the “Company”) an emerging leader in the licensed cannabis sector, is pleased to issue the following letter to shareholders from Chief Executive Officer Jimmy Chan.

Dear Sugarmade Shareholders:

The California cannabis market continues to evolve, creating opportunities for Sugarmade and its shareholders.

While there is undoubtedly short-term turbulence in the market, we believe the long-term outlook of the cannabis industry is very bright, especially for California producers and distributors. Historically, California-grown cannabis has always been highly desirable in the marketplace. Sugarmade believes this will continue as legalization at the U.S. federal level creates substantial opportunities to supply other states with top-grade California-grown cannabis. Thus, we expect our Company will continue to be well-positioned moving forward, especially as our large Lemon Glow property comes online.

Over the shorter term, we see some strategic opportunities for Sugarmade to exploit some of the current marketplace inefficiencies and uncertainties. Over the past few years, there has been a proliferation of large and well-financed multistate operators entering the California marketplace. The regulatory environment remains uncertain, while excise and other taxes imposed on cannabis companies stay at high levels, making it difficult for many operators to produce profits. Aside from those mentioned above, unlicensed cultivators were entering the market due to the prior years price hikes, thus creating additional competition and uncertainty.

While the impact of these issues has been numerous, perhaps the most significant factor facing many cannabis operators in California is the precipitous drop in prices for cultivated cannabis products. It is not uncommon to see spot prices exceed the cost of production and the taxes paid on cultivated cannabis. This situation has forced numerous cannabis cultivation license holders, including unlicensed growers, to forgo plans to directly cultivate cannabis this year.

Sugarmade believes these significant changes in the marketplace create an opportunity to invoke a new short-term strategy while our long-term plans to cultivate at our new Lemon Glow facility are developing. In May of last year, we closed on our acquisition of Lemon Glow Company and announced our plans to acquire the necessary approvals and permits to cultivate up to 32 acres of the 640-acre property. We have also announced that we obtained a conditional use permit number from the community development department of the county of Lake, California, which we believe was an important step toward gaining the full conditional use permit allowing us to cultivate cannabis at the property.

For the 2022 cannabis cultivation season, we are embarking on a new and bold strategy to enter into contract cultivation arrangements with local Lake County, California, cultivators that have decided not to engage in their own cultivation efforts for the 2022 season. These operators have already made significant investments in infrastructure and have highly specialized personnel available that we can utilize on a contract basis for our production of cannabis.

By contracting with the owners of these already available resources, Sugarmade will gain immediate access to the marketplace based on an advantageous cost model that will place Sugarmade on par, or in some cases, at a superior cost position compared to many of the larger cannabis cultivation and distribution companies in the industry.

We are in negotiations with several local permitted and licensed operators that are agreeable to a partnership arrangement with Sugarmade to manage operations for cannabis cultivation. We are also in active negotiations on the distribution side of the business that will allow Sugarmade to bring this cultivated cannabis to the marketplace.

Invoking this dynamic short-term strategy, while continuing to develop our longer-term strategy to fully develop the large Lemon Glow property for cultivation, will allow Sugarmade to significantly advance the timeframe for gaining market share in this industry – and we believe we will be able to do so based on a cost model that will allow us to produce strong margins this cultivation season.

Please stay tuned as we soon provide more information about this exciting change to our strategic path, and as always, we truly appreciate your continued support.

Sincerely,

Jimmy Chan

CEO

About Sugarmade
Sugarmade, Inc. (OTC Pink: SGMD) is a product and branding marketing company investing in operations and technologies with disruptive potential. Our Brand portfolio includes CarryOutsupplies.com, SugarRush, NUG Avenue, Lemon Glow and Budcars.

For more information, please visitwww.Sugarmade.com.

FORWARD-LOOKING STATEMENTS:This release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management’s current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “would,” “could,” “will” and other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward-looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance.

Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company’s actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others, such as but not limited to; economic conditions, changes in the laws or regulations, demand for products and services of the company, the effects of competition, uncontrollable forces of nature and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements.

Any forward-looking information provided in this release should be considered with these factors in mind. We assume no obligation to update any forward-looking statements contained in this report.

Corporate Contact:
Jimmy Chan
+1-(888)-982-1628
info@Sugarmade.com

Investor Relations Contact:
EDM Media, LLC
https://edm.media

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

Digipath Validates and Receives Approval to Use Free DNA Removal to Test for Aspergillus (DIGP)

Holly Neff Cannabis Corner, News May 02nd, 2022

LAS VEGAS, NV, May 02, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Digipath, Inc. (OTCQB: DIGP) (“Digipath” or the “Company”), a service-oriented independent analytical testing laboratory, and data analytics firm focused on the cannabis and hemp markets is pleased to announce that it has received approval of their recent validation to test for Aspergillus using free DNA removal. This AOAC approved test allows Digipath Labs to determine if the Aspergillus found on cannabis and hemp products is alive.

The integration of PCR (the polymerase chain reaction method used to amplify and detect specific sequences of DNA) into The State’s consumption safety requirements for cannabis has caused a steep increase in test failure for the cultivation community. The detection of disease-causing Aspergillus has become a devastating source of cannabis crop loss, significantly impacting growers’ sellable cannabis products. The validation and state approval now allows Digipath to be on the cutting edge of microbiology analysis by determining whether the Aspergillus found on product is alive or dead.

“Aspergillus is one of the most common industry-wide causes of cannabis product testing failure. Since PCR has become the required method for routine micro testing, one of the major challenges has been the potential detection of DNA from dead Aspergillus cells,” stated Criselda Heather, Microbiology and QC Manager, Digipath Labs, Inc. “The Free DNA Removal Solution provides an ideal way to remove the free DNA of dead Aspergillus cells from samples prior to PCR analysis.”

“This ultimately delivers a more accurate depiction of any live Aspergillus DNA present in any given sample of cannabis or hemp. Free DNA Removal prior to PCR can also provide the cultivator with an important tool to determine the efficacy of any mitigation practices for Aspergillus contamination,” Heather added.

About Digipath, Inc. (OTCQB: DIGP)

Digipath, Inc., supports the cannabis industry’s best practices for reliable testing, data acquisition, formulations, and new canna-tech to the cannabis industry. The “Digipath Data Vault” is a rich data set of over 70,000 cannabis chemo profiles which can be used for research and product development in a wide variety of applications.

Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its clients’ products through analysis, research, development, and standardization.

Information about Forward-Looking Statements

This press release contains “forward-looking statements” that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company’s inability to consummate the closing of the Steep Hill acquisition, need for additional funding, the demand for the Company’s products, governmental regulation of the cannabis industry, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Corporate Contact:
Digipath, Inc.
702-527-2060

Investor Relations & Financial Media
Integrity Media
team@integritymedia.com
Toll Free: (888) 216-3595
www.IntegrityMedia.com

Nicola Mining Receives Rock Quarry Permit and Has Commenced Supplying the Ministry of Transport for Highway Infrastructure Repair (HUSIF)

Holly Neff Minning Pit, News May 02nd, 2022

Vancouver, British Columbia–(Newsfile Corp. – May 2, 2022) – Nicola Mining Inc. (TSXV: NIM) (FSE: HLI), (the “Company” or “Nicola“) is pleased to announce that on March 29, 2022, it successfully received a Notice of Departure (“NoD“) at the New Craigmont Project from the Ministry of Energy, Mines and Low Carbon Innovation (“EMLI“). The NoD on the Company’s M-68 Permit allows for the extraction of up to 3.0 million tonnes (“Mt“) of inert available rock material that may be used for the infrastructure reconstruction efforts at a production rate of approximately 1500 tonnes per day. Under the Mineral Tenure Act, receipt of the NoD permits mining and extraction of material; however, to export the material from the mine site for commercial purposes, the Company was required to engage with First Nations and receive separate approval from the Ministry of Forests^[1] (“FLNR“).

On April 13, 2022, the Company received License Number 349184 from FLNR, which allows the site to produce and remove riprap and associated products from its rock quarry for five years. The Company is also pleased to announce that its rock quarry partner, Lower Nicola Site Services Ltd.^[2] (“LNSS“), has subsequently entered into an agreement to supply the Ministry of Transport and Infrastructure (“MOTI“) with riprap from the Company’s site.

Nicola receives a royalty for rock material transported from its site.

The material supplied from the Company’s quarry is expected to aid MOTI in its repairing of the Trans-Canada Highway, Highway 99, Highway 7, Highway 3, Highway 5, and Highway 8, which were damaged by the flooding events that occurred in November of 2021. Nicola is to receive a per tonne royalty for extracted material.

Peter Espig, Chief Executive Officer, commented, “The opportunity to work with LNSS on our rock quarry represents much more than a new revenue stream; it highlights our community relations initiatives and allows communities to benefit from our efforts. Currently, we are in the process of applying for a gravel quarry permit, which will further augment our revenues and benefit communities.”

Qualified Person

James N. Gray, P.Geo, a consulting geologist to the Company, is the independent qualified person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects for the technical disclosure contained in this news release.

About Nicola Mining

Nicola Mining Inc. is a junior mining company listed on the TSX Venture and Frankfurt Exchanges that maintains a 100% owned mill and tailings facility, located near Merritt, British Columbia. It has signed Mining and Milling Profit Share Agreements with high grade gold projects. Nicola’s fully-permitted mill can process both gold and silver mill feed via gravity and flotation processes.

The Company owns 100% of the New Craigmont Project, a high-grade copper property, which covers an area of 10,913 hectares along the southern end of the Guichon Batholith and is adjacent to Teck Resources Ltd.’s Highland Valley Copper, Canada’s largest copper mine. The Company also owns 100% of the Treasure Mountain Property, consisting of 30 mineral tenures covering 513 hectares (ha) and a mining lease covering 335 ha.

On behalf of the Board of Directors

“Peter Espig“

Peter Espig
CEO & Director

For additional information

Contact: Peter Espig
Phone: (778) 385-1213
Email: info@nicolamining.com

Forward-Looking Information

Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, statements regarding the allocation of revenues and royalties under the Agreement towards Nicola’s site maintenance, including annual reports and reclamation obligations and that Nicola will continue to work closely with previously engaged consultants and service providers. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company. These risks include, but are not limited to, changes in Nicola’s business relationships and plans, changes in the anticipated uses of revenues and royalties under the Agreement, the failure of Nicola to receive the necessary approvals for the NoD from the EMLI, as well as other general business, economic, or market related risks beyond the director control of the Company and which may affect the Company’s business and operations. The novel strain of coronavirus, COVID-19, also continues to pose risks that are currently indescribable and immeasurable. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, unless required by law. The reader is cautioned not to place undue reliance on forward-looking information.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

^[1] The Ministry of Forests is responsible for the stewardship of provincial Crown land and ensures the sustainable management of forest, wildlife, water, and other land-based resources. The Ministry works with Indigenous and rural communities to strengthen and diversify their economies.

^[2] In its March 14, 2022, news release the Company announced that it had entered into an agreement with Lower Nicola Site Services Ltd. (“LNSS“) to extract gravel and rock from the Company’s Craigmont Mine Site.

International Patent Application Filed for Cervical Cancer Vaccine (BVAXF)

Holly Neff Biotech Corner, News May 02nd, 2022

VANCOUVER, BC, May 2, 2022 /CNW/ — BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has continued to expand the patent coverage for its cancer vaccine platform by filing an international patent application through the Patent Cooperation Treaty (“PCT”) for broad geographic market coverage outside the US for cervical cancer. BioVaxys has an agreement with Procare Health of Barcelona, Spain (“Procare”) for clinical co-development of the Company’s autologous bihaptenized cervical cancer vaccine for the EU market, in addition jointly conducting the upcoming EU Phase I clinical study of BVX-0918 in ovarian cancer.

The International Patent Cooperation Treaty (“PCT”) Application, which is a patent treaty with more than 150 member countries, makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single “international” patent application instead of filing several separate national or regional patent applications.

BioVaxys’ vaccine platform is based on the established immunological concept that modifying surface proteins—whether they are viral or tumor—with haptens makes them more visible to the immune system. This process of haptenization “teaches” a patient’s immune system to recognize and make target proteins more “visible” as foreign, thereby stimulating a T-cell mediated immune response. BioVaxys’ cancer vaccines are created by extracting a patient’s own (autologous) cancer cells, chemically linking with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic. Haptenization is a well-known and well-studied immunotherapeutic approach to cancer immunotherapy and has been clinically evaluated in both regional and disseminated metastatic tumors.

In addition to ovarian cancer and cervical cancer, the Company recently announced its plans to conduct an investigator-sponsored clinical study of its vaccine platform in colorectal cancer.

About BioVaxys Technology Corp.

Based in Vancouver, BioVaxys Technology Corp. (www.biovaxys.com) is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).

ON BEHALF OF THE BOARD

Signed “James Passin”
James Passin, CEO
+1 646 452 7054

Government & Media Relations

JB&A, Inc.
Davin Shinedling
davin@jennibyrne.com
1 (647) 991-6447

Cautionary Statements Regarding Forward Looking Information

This press release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or “should” occur or be achieved. Forward-looking statements in this news release relate to, among other things, completion of the murine model study, regulatory approval for a Phase I study of its BVX-0320 Vaccine Candidate in humans and the overall development of BioVaxys’ vaccines, including any haptenized SARS-Cov-2 protein vaccine. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.

These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys’ vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys’ business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

View original content:https://www.prnewswire.com/news-releases/international-patent-application-filed-for-cervical-cancer-vaccine-301536798.html

SOURCE BioVaxys Technology Corp.

US Nuclear and Solar System Resources Building the Future of the Global Space & Energy Sector (UCLE)

Holly Neff News, Other Corner May 02nd, 2022

LOS ANGELES, May 02, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – US Nuclear Corp. (OTC-QB: UCLE) and their partner Solar System Resources Corporation have been actively working to develop the future of space mining and technology, with an emphasis on procuring Helium-3, Lithium, Cobalt and rare metals which are desperately needed as energy sources for batteries, advanced microchips and especially for clean, renewable fusion power.

To help pave the way for sure to come space mining expeditions, AGH University of Science and Technology in Poland launched new studies in space mining, and a significant share in their creation was played by Solar System Resources Corporation Sp. z o. o., with cooperation of investor and partner US Nuclear Corp.

On Wednesday, April 27, 2022, the AGH University of Science and Technology senate approved the establishment of a new specialization in “Space Drilling” studies. It will concern the conversion of Earth’s drilling and mining technologies to space conditions. The faculty of terrestrial Drilling, Oil and Gas at AGH have been involved in the development of space technologies in Poland for over 11 years.

Work on the preparation of the specialty lasted over a year. A member of the team working on this specialization was the CEO of Solar System Resources- Ph.D. Eng. Adam Jan Zwierzyński. The new specialty has consulted with specialists from the space industry (including the European Space Agency (ESA) and UNIVERSEH) and was supported by institutions and companies in the Polish space sector, including Solar System Resources.

The planned date of launching the studies is March 2023. The studies will be launched in Polish, but in the event of high interest, it is also planned to open studies in English in the near future. More information about these studies is available at the following e-mail address: spacedrilling@agh.edu.pl

Solar System Resources and US Nuclear Corp. have been actively working for a long time on the development of the global space industry and Poland’s stronger involvement in public and commercial space exploration programs. For the purposes of effective transatlantic cooperation, they established American joint-venture company USN Solar Sky Mining LLC.

Solar System Resources, as a space mining lobbyist, registered in Poland and at the European Parliament in 2020 and 2021, actively lobbying for Poland’s accession to the international agreement Artemis Accords. Thanks to these efforts and other interested persons, the President of the Polish Space Agency signed in October 2021 Poland’s accession to the international agreement Artemis Accords.

In February 2021, the US Nuclear Corp. and Solar System Resources were the first in the world to sign a historic letter of intent for the supply of 500 kg of helium-3. In the preamble to this document, both companies expressed the need for radical measures to protect the climate through the development of ecological energy sources, such as fusion based on helium-3.

Solar System Resources Corporation Sp. z o. o. is recognized in recent report “Helium-3 Market by Application (Oil & Gas, Defense, Medical, Power Plant, Others), and by Region, Forecast to 2028” (https://www.reportsanddata.com/report-detail/helium-3-market) as one of the 5 major global players on the Helium-3 market.

Then, in April 2021, the US Nuclear and Solar Resources signed a MoU, a historic transatlantic trade deal to create a Cis-Lunar value chain. The agreement also mentions the intention to create in the future strategic reserves of raw materials in space for the needs of the United States and its allies.

Under both of these agreements, US Nuclear Corp. obtained exclusive rights to receive and distribute a broad range of space resources to be supplied in the future by Solar System Resources (including helium-3, industrial metals) on the North American market. Solar System Resources obtained in the territory of the EU, Ukraine and the Middle East, exclusive rights for the supply and sale of parts of future technologies and services developed by the US Nuclear Corp.

Safe Harbor Act

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.com.

CONTACT:

US Nuclear Corp. (OTC-QB: UCLE)
Robert I. Goldstein, President, CEO, and Chairman
Rachel Boulds, Chief Financial Officer
(818) 883 7043
Email: info@usnuclearcorp.com

Glass House Brands Completes Acquisition of PLUS, a Leading California Edibles Brand (GLASF)

Holly Neff Cannabis Corner, News Apr 30th, 2022

– Acquisition Establishes Glass House as the Only Company with a Top 5 Position in Both the Flower and Edibles categories in California¹ –

LONG BEACH, Calif. and TORONTO, April 29, 2022 /PRNewswire/ — Glass House Brands Inc. (“Glass House” or the “Company”) (NEO: GLAS.A.U and GLAS.WT.U)(OTCQX: GLASF and GHBWF), one of the fastest- growing, vertically-integrated cannabis companies in the U.S., and Plus Products Inc. (“PLUS”) today announced that Glass House has completed the acquisition of the business of PLUS, a leading cannabis edibles company based in California². The Company acquired PLUS for approximately US$25.6 million³ through a combination of unsecured convertible debt⁴ and equity, plus additional performance-based consideration.

“With a mission to create the largest cannabis brand-building platform in California, we are thrilled to announce the closing of our PLUS acquisition, positioning Glass House as the only company with a top 5 position in both the Flower and Edibles segments in the California market,” said Kyle Kazan, Glass House’s Chairman and Chief Executive Officer. “Edibles are a key component of our growth strategy as we further expand our product portfolio and build stronger brand awareness. We are incredibly excited to begin our work with the PLUS team to expand the presence of their premium products in our own retail stores and across our distribution network. The combination of our existing brand platform with PLUS will result in a substantial increase in our Total Addressable Market (“TAM”) opportunity in California and, eventually, across the US. The overlap between Glass House Brands’ active accounts and those of PLUS was less than 25% in the first quarter, with Glass House being stronger in Southern California and PLUS stronger in Northern California. Additionally, we aim to grow the PLUS brand nationally, which would expand its TAM by roughly 550% versus operating in California alone⁵.”

Mr. Kazan added, “The upside of the current struggle in the California market is that we believe we will find more attractively valued acquisition targets that are win-win propositions for all parties including the consumer. We look forward to entering this new stage of growth by executing on PLUS’ and Glass House’s shared vision of bringing innovative, high quality cannabis products to consumers.”

The Company’s house cannabis brand, Glass House Farms, was the No. 1 ranked flower brand by sales in California in Q1 2022⁶. PLUS is a leading edibles brand in California and was the No. 4 ranked edibles brand in California by sales in Q1 2022⁶. Based on top-of-mind brand awareness, a common CPG metric measuring brand strength, PLUS is the No. 1 ranked brand in California in the gummy segment, the largest segment of the edibles category⁷.

Sources:
1. BDS Analytics
2. Specifically, the Company acquired the US business assets of Plus Products Inc. by merging wholly-owned subsidiary with Plus Products Holdings Inc., a wholly-owned subsidiary of PLUS.
3. Based on the trailing 10-day volume-weighted average price (“VWAP”) of Glass House Shares on the NEO prior to the date of execution of the definitive acquisition agreement on December 17, 2021 ($4.08 as of 12/16/21 close). Assuming the full vesting of the 1,794,791 RSUs that will be granted as part of the transaction the total purchase price would be approximately $33m.
4. $20,504,850.96 CAD principal and accrued interest converted at 0.78 CAD:USD
5. Based on BDSA 2026e Cannabis Market size projections for the US (US$46bn) and for California (US$7.1bn).
6. BDSA Retail Sales Tracking
7. Brightfield Consumer Study (N = 1,535 California Edible Consumers)

About PLUS
PLUS is a cannabis and hemp food company focused on using nature to bring balance to consumers’ lives. PLUS’s mission is to make cannabis safe and approachable – that begins with high-quality products that deliver consistent consumer experiences. PLUS is headquartered in San Mateo, CA.

About Glass House Brands
Glass House Brands is one of the fastest-growing, vertically integrated cannabis companies in the U.S., with a dedicated focus on the California market and building leading, lasting brands to serve consumers across all segments. From its greenhouse cultivation operations to its manufacturing practices, from brand-building to retailing, the company’s efforts are rooted in the respect for people, the environment, and the community that co-founders Kyle Kazan, Chairman and Chief Executive Officer, and Graham Farrar, Board Member and President, instilled at the outset. Through its portfolio of brands, which includes Glass House Farms, Forbidden Flowers, and Mama Sue Wellness, Glass House Brands is committed to realizing its vision of excellence: outstanding cannabis products, produced sustainably, for the benefit of all. For more information and company updates, visit www.glasshousebrands.com and https://ir.glasshousebrands.com/contact/email-alerts/.

Forward Looking Statements
This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as “forward-looking statements”), including with respect to the Company, on a post-combination basis, being the only company with a top 5 position in both the Flower and Edibles categories in California; the Company’s vertically integrated platform allowing Glass House to expand the presence of its premium products in its own retail stores and across its distribution network; and for the Company achieving top sales rankings in both flower and edibles categories in California. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements, including the ability of the Company to expand the presence of its premium products in its own retail stores and across its distribution network, and the Company achieving top sales rankings in both flower and edibles categories in California, among other factors. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

For more information on the Company, investors are encouraged to review the Company’s public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

For further information, please contact:
Glass House Brands Inc.
John Brebeck, Vice President of Investor Relations
T: (562) 264 5078
ir@glasshousebrands.com

Jamin Horn, General Counsel and Corporate Secretary
T: (562) 264 5078
jamin@glasshousegroup.com

Investor Relations Contact:
MATTIO Communications
T: (416) 992-4539
ir@mattio.com

Media Relations Contact:
MATTIO Communications
Public Relations
glasshouse@mattio.com

View original content:https://www.prnewswire.com/news-releases/glass-house-brands-completes-acquisition-of-plus-a-leading-california-edibles-brand-301536485.html

SOURCE PLUS

IR-Med Announces $3.2 Million Private Placement (IRME)

Holly Neff Biotech Corner, News Apr 30th, 2022

IR-Med (“IR-MED or the “Company”) (OTCQB:IRME), an innovative development stage medical device company that utilizes Infra-Red light spectroscopy (IR) combined with Artificial Intelligence (AI) technologies, announced that it has entered into a Subscription Agreements with certain investors for the sale of 3,636,364 shares at a per share price of $0.88 and warrants to purchase up to an additional 3,636,364 shares of common stock at a per share exercise price of $1.10. The Company received aggregate gross proceeds of $3,200,000.

The Company intends to use the proceeds for general corporate purposes and to advance the development of its product candidates.

“This financial commitment from our investors who include existing shareholders further strengthens our balance sheet and provides for additional future funding” remarked Dr. Rom Eliaz, the Company’s CEO.

The securities may not be offered or sold in the United States absent registration or pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. The Company has agreed to file a registration statement covering the resale of the shares of common stock acquired by the investors and shares of common stock issuable upon exercise of the warrants acquired by the investors.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be by means of a prospectus.

About IR-MED

IR-MED Inc., is developing a non-invasive spectrographic analysis technology platform, allowing healthcare professions to detect and measure different molecules in the blood and in human tissue in real-time without any invasive procedures. The first product under development is a handheld optical monitoring device that is being developed to support early detection of pressure injuries (PI) to the skin and underlying tissue, regardless of skin tone and which calibrated personally to each patient’s skin, primarily caused by prolonged pressure associated with bed confinement. IR-MED skin-device-interphase development of personalized medical devices allows high accuracy readings from the human body in a non-invasive method, that may provide caregiver the optimal decision support-system in cases where uncertainties disturb physicians in their decision processes.

IR-MED holds patents protecting its innovation in the noninvasive tissue analysis, and in the modeling and analysis of subcutaneous tissue.

Safe Harbor Statement / Forward-Looking Statements

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of IR-MED are subject to many factors including, but not limited to, the sufficiency or working capital and our ability to raise the capital needed to fund our development efforts, results of clinical studies and trials, timing of product development, FDA approval/clearance of products in development, customer acceptance of our products in the market, the introduction of competitive products, the impact of any product liability or other adverse litigation, commercialization and technological difficulties, and the other risks identified in our most recent annual report on Form 10-K filed on March 31, 2022 with the Securities and Exchange Commission. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.

Kane Biotech Announces Extension of Private Placement Offering (KNE)

Holly Neff Biotech Corner, News Apr 30th, 2022

WINNIPEG, Manitoba, April 29, 2022 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) today announced that it has extended the completion of its previously announced non-brokered private placement offering (the “Offering”) by 30 days until May 29, 2022.

The terms of the Offering remain unchanged from those described in the press release dated March 15, 2022 and the Offering remains subject to receipt of all necessary approvals, including the approval of the TSX Venture Exchange.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. These securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.

About Kane Biotech

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (81 patents and patents pending, trade secrets and trademarks) and products developed by the Company’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB^®, Aledex™, bluestem™, bluestem^®, silkstem™, goldstem™, coactiv+™, coactiv+^®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech. The Company is listed on the TSX Venture Exchange under the symbol “KNE” and on the OTCQB Venture Market under the symbol “KNBIF”.

For more information:

Marc Edwards	Ray Dupuis	Nicole Sendey
Chief Executive Officer	Chief Financial Officer	Investor Relations/PR
Kane Biotech Inc	Kane Biotech Inc	Kane Biotech Inc
medwards@kanebiotech.com	rdupuis@kanebiotech.com	nsendey@kanebiotech.com
+1 (514) 910-6991	+1 (204) 298-2200	+1 (250) 327-8675

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.

Danavation Technologies Announces Appointment of Chief Financial Officer (DVNCF)

Holly Neff News, Other Corner Apr 30th, 2022

TORONTO, April 29, 2022 /CNW/ – Danavation Technologies Corp. (CSE: DVN) (OTCQB: DVNCF) (“Danavation” or the “Company“) is pleased to announce the appointment of Kyle Nazareth as Chief Financial Officer of the Company effective May 2, 2022.

Mr. Nazareth brings with him over eight years of finance experience in positions ranging from Finance Manager to Chief Financial Officer. He is a co-founder and principal at Jaeger Financial LLP, a Toronto-based firm focused on providing fractional CFO services and financial compliance consulting at a high quality and on a cost efficient basis. Kyle brings a proven track record in the CFO role providing extensive finance and capital markets expertise to clients in high-growth sectors. He is a CA, CPA and holds a BBA degree from the Schulich School of Business at York University. Mr. Nazareth assumes the role from Mr. Mike Emslie, who had served as the Company’s CFO since July, 2021.

“We are very pleased to welcome Kyle to the Danavation team at a pivotal time in our life-cycle with an expanding client portfolio and growing geographic footprint. His knowledge, expertise and hands-on CFO experience will be instrumental in taking us through the next phase of our growth strategy,” said John Ricci, CEO of Danavation. “On behalf of Danavation and our Board of Directors, we appreciate Mike’s support to date and wish him all the best in his future endeavours.”

About Danavation

Danavation Technologies Corp. is a Canadian-based, Internet of Things (IoT) technology company, providing micro e-paper displays to organizations across North America. The Company’s Digital Smart Labels™, powered by IoT automation technology and software Platform-as-a-Service (PaaS), enables companies across various sectors to automate labelling, price, product, and promotions in real-time, enhancing data accuracy and improving performance by removing high labour costs and low productivity associated with traditional labour-intensive workflows. By empowering the adoption of smart retail, smart cities and industry 4.0, our goal is to create a sustainable and profitable business for shareholders while advancing sound environmental, social and governance practices, including by significantly reducing paper usage. Danavation has introduced its solution to retailers across North America, including big box and boutique grocers, while also targeting new markets including healthcare providers, manufacturing, and logistics companies. Learn more about the background of Danavation and our vision for the future on our website. As well, follow us on LinkedIn, Instagram, Twitter and YouTube for more updates on how we are transforming the retail landscape.

Forward-Looking Information

This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating, the future business of the Company, potential roll outs of the Company’s products and services, further business from the Company’s clients, industry outlook and potential and other matters. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Company. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Danavation Technologies Corp.

Jaguar Mining Completes Filing of Technical Reports (JAGGF)

Holly Neff Minning Pit, News Apr 29th, 2022

TORONTO, ON / ACCESSWIRE / April 29, 2022 / Jaguar Mining Inc. (“Jaguar” or the “Company”) (TSX:JAG)(OTCQX:JAGGF) is pleased to report that it has completed the filing of independent National Instrument 43-101 (“NI 43-101”) “Technical Reports on the Turmalina and Pilar Gold Mines, respectively, (the “Technical Report”). The Technical Report supports the Company’s updated Mineral Reserves and Mineral Resources announced in a news release dated March 31, 2022. All Company Technical Reports are available on SEDAR (www.sedar.com) and on the Company’s website.

About Jaguar Mining Inc.

Jaguar Mining Inc. is a Canadian-listed junior gold mining, development, and exploration company operating in Brazil with three gold mining complexes, and a large land package with significant upside exploration potential from mineral claims covering an area of approximately 56,000 hectares. The Company’s principal operating assets are located in the Iron Quadrangle, a prolific greenstone belt in the state of Minas Gerais and include the Turmalina Gold Mine Complex and Caeté Gold Mine Complex. The Company also owns the Paciência Gold Mine Complex, which has been on care and maintenance since 2012. Additional information is available on the Company’s website at www.jaguarmining.com.

For further information, please contact:

Vern Baker
Chief Executive Officer
Jaguar Mining Inc.
vbaker@jaguarmining.com
+55 (31) 3232-7101

Hashim Ahmed
Chief Financial Officer
Jaguar Mining Inc.
hashim.ahmed@jaguarmining.com
416-847-1854

SOURCE: Jaguar Mining Inc.